Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer.

Dr. David Kerr reports on a Korean meta-analysis that clearly supports use of second-line chemotherapy in locally advanced or metastatic gastric cancer at the time of relapse.

Capsule endoscopy is contraindicated in patients with implantable cardiac devices per the current recommendations. Is that still valid? Maybe not. Dr. David Johnson explores the latest evidence.

Paul G. Auwaerter, MD, says it is too early to know whether the FDA voluntary phase-out of antibiotics in animals will make a real difference.

Although common in many people, when these symptoms are chronic, persistent, and intractable, they can be difficult to manage.

Which patients are most vulnerable to serious illness with antibiotic-resistant Salmonella?

Dr. David Johnson presents his top 10 key scientific presentations from this year's American College of Gastroenterology meeting in San Diego.

Dr. David Kerr reports on provocative data from the FIRE-3 study indicating that cetuximab plus FOLFIRI confers a 7.5-month survival advantage in patients with wild-type KRAS colorectal cancer.

Is molecular profiling integral to choice of treatment or simply a source of confusion? Dr. John Marshall speaks to issues that need to be resolved before 'personalized medicine' is practice-ready.

FDA Commissioner Margaret Hamburg, MD, talks with Medscape at the National Health Research Forum in Washington, DC.